Psychologist Anna Graf support children and adolescents who are undergoing cancer treatment at the University Children’s Hospital. Her tools include toys, books and colorful glass beads.
Pediatric oncologist Jean-Pierre Bourquin is working to develop gentler therapies and seeking ways of tackling aggressive forms of blood cancer more effectively.
Kilian Käslin developed leukemia as a baby. The diagnosis marked the start of a months-long battle for his life that required his family and doctors to give their all.
Today, many children with cancer can be treated successfully. A new Center of Competence in Research aims to make treatments even more targeted and effective. Read more in the UZH Magazin.
Raphael Morscher, of the University Children’s Hospital Zurich, received the award for his research examining the metabolism of cancer cells as a potential therapeutic approach for neuroblastoma.
Hereditary Epilepsy Successfully Treated in Mouse Model
Scientists used gene editing to fix faulty DNA directly in the brain cells of mice, which reduced fever-induced seizures and markedly improved survival rates in an animal model.
Antibody Spurs Nerve Fiber Regrowth Following Spinal Cord Injury
Scientists at UZH and Balgrist University Hospital reveal for the first time how the antibody therapy works: new nerve fibers were found to form functional connections once again.
The Role of Gut Bacteria in Boosting Cancer Treatment
New research from Zurich shows that the gut microbiome may have an impact on cancer immunotherapy, giving patients who did not initially respond to treatment a second chance.
At UZH, basic research brings about innovative products and applications. Researchers at UZH filed several patents in 2025, and four new spin-offs were created.
Alzheimer’s Drug Demonstrates Efficacy Against Sickle Cell Anemia
Memantine, a cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data indicate that the active ingredient is well tolerated.
Researchers at UZH have been working on bio-engineered skin grafts for over 15 years, leading to the founding of spin-off Cutiss that produces living skin tissue from the patients’ own cells.
Genetic Risk Factor and Viral Infection Jointly Contribute to MS
In addition to an infection with the Epstein-Barr virus, certain gene variants are also partly responsible for triggering MS. Together, these two risk factors lead to the autoimmune disease.
How can we influence whether we develop Alzheimer’s disease? Researchers at UZH are examining the factors that trigger the onset of the disease – and those that shield us against it.